SCHOTT Pharma (1SXP) investor relations material

Executive summary

• Q1 2026 revenue rose 4.8% at constant currencies to EUR 240 million, driven by strong demand for high-value solutions (HVS), which reached a 57% revenue share, up 2 percentage points year-over-year.

• EBITDA increased by 11.1% to EUR 65.2 million, with margin improving to 27.1%, mainly due to HVS and especially drug containment solutions.

• Net income rose 12% year-over-year to EUR 33.3 million, with EPS at EUR 0.22.

• Strategic focus remains on innovation, expansion, and partnerships, with new product launches and expanded HVS capacity in Switzerland and Hungary.

• Strategy aligns with pharma trends, emphasizing innovation and trusted partnerships.

Financial highlights

• Revenue: EUR 240.2 million, up 3.8% year-over-year (4.8% at constant currencies).

• EBITDA: EUR 65.2 million, up 11.1% year-over-year; margin expanded to 27.1%.

• EBIT: EUR 43.8 million, up 9% year-over-year; net income: EUR 33.3 million, up 12%; EPS at EUR 0.22.

• Free cash flow at EUR -20 million, impacted by a deferred customer payment; capital expenditure reached EUR 23.4 million.

• Equity ratio improved to 57.3% from 55.9% at the prior year-end.

Outlook and guidance

• FY 2026 guidance confirmed: organic revenue growth of 2%-5% at constant currencies, EBITDA margin around 27%, and CAPEX of EUR 140–160 million.

• HVS revenue share expected to remain robust at 57%.

• Effective tax rate for the year assumed at 22%.

• Assumptions include stable exchange rates and no major disruptions.